Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LRMR Larimar Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: LRMR
Price (delayed)
$2.24
Market cap
$143.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$126.56M
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical
Highlights
The debt has contracted by 9% YoY and by 4.9% from the previous quarter
The company's net income has shrunk by 111% YoY and by 18% QoQ
LRMR's quick ratio has dropped by 60% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of LRMR
Market
Valuations
Earnings
Shares outstanding
64.03M
Market cap
$143.42M
Enterprise value
$126.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$105.34M
Net income
-$95.23M
EBIT
-$95.23M
EBITDA
-$95.11M
Free cash flow
-$87.45M
Per share
Balance sheet
Liquidity
EPS
-$1.5
EPS diluted
-$1.5
Free cash flow per share
-$1.37
Book value per share
$2.25
Revenue per share
$0
TBVPS
$2.66
Total assets
$170.18M
Total liabilities
$25.9M
Debt
$4.87M
Equity
$144.27M
Working capital
$143.35M
Debt to equity
0.03
Current ratio
7.48
Quick ratio
7.14
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.1%
Return on equity
-52.5%
Return on invested capital
-59.7%
Return on capital employed
-64.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LRMR stock price
How has the Larimar Therapeutics stock price performed over time
Intraday
3.23%
1 week
-21.68%
1 month
30.99%
1 year
-71.72%
YTD
-42.12%
QTD
4.19%
Financial performance
How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$105.34M
Net income
-$95.23M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 111% YoY and by 18% QoQ
Larimar Therapeutics's operating income has shrunk by 107% YoY and by 16% QoQ
Price vs fundamentals
How does LRMR's price correlate with its fundamentals
Growth
What is Larimar Therapeutics's growth rate over time
Valuation
What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 56% YoY and by 14% from the previous quarter
LRMR's P/B is 48% below its 5-year quarterly average of 1.9 and 42% below its last 4 quarters average of 1.7
LRMR's equity is down by 38% year-on-year and by 16% since the previous quarter
Efficiency
How efficient is Larimar Therapeutics business performance
LRMR's ROE is down by 47% year-on-year and by 32% since the previous quarter
Larimar Therapeutics's ROA has decreased by 43% YoY and by 29% from the previous quarter
The ROIC has contracted by 18% from the previous quarter but it has grown by 11% YoY
Dividends
What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LRMR.
Financial health
How did Larimar Therapeutics financials performed over time
LRMR's quick ratio has dropped by 60% year-on-year and by 6% since the previous quarter
The current ratio has dropped by 58% year-on-year and by 7% since the previous quarter
The debt is 97% less than the equity
LRMR's debt to equity has soared by 50% YoY
LRMR's equity is down by 38% year-on-year and by 16% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.